From: Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs
Sample type | Nasal swabs (by day) | BALF | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Treatment group | 2 dpc | 4 dpc | 5 dpc | 6 dpc | At necropsy (7 dpc) | |||||||||||||||
PRa | Ct valueb | H1d | H3 | PR | Ct value | H1 | H3 | PR | Ct value | H1 | H3 | PR | Ct value | H1 | H3 | PR | Ct value | H1 | H3 | |
COM/COM | 1/10 | 43.54 (4.61)c A | 0/10 | 0/10 | 2/10 | 41.95 (6.67)A | 0/10 | 1/10 | 5/10 | 39.06 (7.41)A | 0/10 | 1/10 | 3/10 | 40.26 (8.50)A | 0/10 | 1/10 | 6/10 | 32.90 (11.70)BC | 1/10 | 4/10 |
AUT/AUT | 1/10 | 43.66 (2.85)A | 0/10 | 0/10 | 5/10 | 39.84 (5.67)A | 1/10 | 0/10 | 5/10 | 38.90 (7.21)A | 1/10 | 0/10 | 1/10 | 43.05 (6.16)A | 1/10 | 0/10 | 3/10 | 40.74 (6.38)A | 1/10 | 1/10 |
AUT/COM | 0/10 | 44.39 (1.84)A | 0/10 | 0/10 | 7/10 | 38.12 (5.02)AB | 0/10 | 0/10 | 5/10 | 40.01 (5.41)A | 0/10 | 1/10 | 0/10 | 44.35 (2.06)A | 0/10 | 0/10 | 1/10 | 43.93 (3.38)A | 0/10 | 0/10 |
COM/AUT | 1/10 | 43.95 (3.33)A | 0/10 | 0/10 | 5/10 | 39.67 (5.74)A | 0/10 | 0/10 | 5/10 | 39.71 (5.76)A | 0/10 | 1/10 | 2/10 | 42.18 (6.31)A | 0/10 | 1/10 | 4/10 | 39.89 (6.76)AB | 0/10 | 2/10 |
NO VAC/CHA | 5/10 | 37.83 (8.02)B | 1/10 | 3/10 | 6/10 | 33.05 (9.71)B | 3/10 | 4/10 | 7/10 | 30.43 (12.09)B | 3/10 | 4/10 | 6/10 | 30.72 (10.89)B | 1/10 | 4/10 | 8/10 | 26.75 (10.75)C | 7/10 | 4/10 |
NO VAC/NO CHA | 0/3 | 45 (0) | 0/3 | 0/3 | 0/3 | 45 (0) | 0/3 | 0/3 | 0/3 | 45 (0) | 0/3 | 0/3 | 0/3 | 45 (0) | 0/3 | 0/3 | 0/3 | 45 (0) | 0/3 | 0/3 |
LAIV/COM | 0/10 | 44.25 (1.83)A | 0/10 | 0/10 | 5/10 | 39.33 (6.51)A | 0/10 | 1/10 | 5/10 | 39.58 (6.09)A | 0/10 | 1/10 | 3/10 | 40.20 (7.76)A | 1/10 | 2/10 | 5/10 | 36.29 (9.66)A | 1/10 | 4/10 |
LAIV/NONE | 7/10 | 36.04 (6.70)B | 1/10 | 3/10 | 6/10 | 32.04 (11.36)B | 2/10 | 4/10 | 8/10 | 29.56 (9.95)B | 3/10 | 4/10 | 7/10 | 32.26 (8.23)B | 2/10 | 4/10 | 10/10 | 23.93 (5.24)B | 7/10 | 6/10 |